D. Mulford

发表

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

Deepak L. Bhatt, A. Michelson, A. L. Frelinger, 2013, Journal of the American College of Cardiology.

A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure

C. Scarpignato, C. Howden, A. Facius, 2021, Journal of clinical pharmacology.

Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry.

D. Mulford, Carl T Whalen, G. Hanson, 2002, Journal of chromatographic science.

Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment

R. Khosravan, D. Mulford, L. Vernillet, 2005, American journal of therapeutics.

Impact on carnitine homeostasis of short‐term treatment with the pivalate prodrug cefditoren pivoxil

C. Hoppel, E. Brass, D. Mulford, 2003, Clinical pharmacology and therapeutics.

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function

G. Granneman, S. Wong, C. Locke, 1997, European Journal of Clinical Pharmacology.

Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy

D. Metz, T. Dixit, D. Mulford, 2009, Alimentary pharmacology & therapeutics.

Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjects.

G. Granneman, Z. Hussein, D. Mulford, 1993, British journal of clinical pharmacology.

Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.

D. Mulford, M. Kukulka, Yusuke Murakawa, 2019, Journal of pharmaceutical sciences.

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials*

D. Mulford, Jing-tao Wu, Weijiang Zhang, 2009 .

Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2004, Nucleosides, nucleotides & nucleic acids.

Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects

L. Laine, Prateek Sharma, B. Hunt, 2022, The American journal of gastroenterology.

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

M. Hibberd, C. Howden, D. Mulford, 2021, Clinical pharmacology in drug development.

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

Ronald D Lee, Deepak L. Bhatt, Deepak L Bhatt, 2012, Journal of the American College of Cardiology.

Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects

J. Freston, Y. Chiu, D. Mulford, 2003, Alimentary pharmacology & therapeutics.

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

C. Scarpignato, I. Michon, H. Jones, 2023, CPT: pharmacometrics & systems pharmacology.

Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects

R. Khosravan, D. Mulford, L. Vernillet, 2011, Journal of clinical pharmacology.

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects

R. Khosravan, D. Mulford, L. Vernillet, 2005 .

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2005 .

Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility

D. Mulford, M. Vakily, J. Wu, 2009, Alimentary pharmacology & therapeutics.

The effect of time‐of‐day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor

R. Lee, D. Mulford, J. Wu, 2010, Alimentary pharmacology & therapeutics.

Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation

L. Gunawardhana, R. Lee, D. Mulford, 2009, Clinical Drug Investigation.

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

D. Mulford, Weijiang Zhang, M. Vakily, 2009, Current medical research and opinion.

S1095 The Pharmacokinetics of TAK-390mr 60 mg, a Dual Delayed Release Formulation of the Proton Pump Inhibitor TAK-390, and Lansoprazole 60 mg: A Retrospective Analysis

D. Mulford, M. Vakily, G. Witt, 2008 .

A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection

C. Scarpignato, C. Howden, A. Facius, 2023, Alimentary pharmacology & therapeutics.

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

A. Michelson, Michael Lampa, M. Barnard, 2012 .

Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2004 .